[HTML][HTML] Distinguishing EGFR mutant subtypes in stage IA non-small cell lung cancer using the presence status of ground glass opacity and final histologic …
J Qiu, Z Ma, R Li, C Qu, K Wang, B Liu, Y Tian… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Background The progression of early stage non-small cell lung cancer (NSCLC) is closely
related to epidermal growth factor receptor (EGFR) mutation status. The purpose of this …
related to epidermal growth factor receptor (EGFR) mutation status. The purpose of this …
[HTML][HTML] Clinical value of alveolar lavage supernatant specimens in the detection of the EGFR gene mutation in patients with non-small cell lung carcinoma
S Han, Y Guo, X Luo, G Tong, C Zhao, Y Li… - Translational Cancer …, 2022 - ncbi.nlm.nih.gov
Background This study sought to compare the consistency of the epidermal growth factor
receptor (EGFR) gene mutation detection results in the supernatant of alveolar lavage …
receptor (EGFR) gene mutation detection results in the supernatant of alveolar lavage …
Role and therapeutic targeting of glutamine metabolism in non‑small cell lung cancer
L Zhou, Q Zhang, Q Zhu, Y Zhan, Y Li… - Oncology …, 2023 - spandidos-publications.com
The Warburg effect indicates that cancer cells survive through glycolysis under aerobic
conditions; as such, the topic of cancer metabolism has aroused interest. It is requisite to …
conditions; as such, the topic of cancer metabolism has aroused interest. It is requisite to …
Evaluation on the Distribution of EGFR, KRAS and BRAF Genes and the Expression of PD-L1 in Different Types of Lung Cancer
R Zhao, S Gao, H He, J Zhang, G Zhang… - International Journal of …, 2021 - Taylor & Francis
Objective To evaluate the distribution of high frequency mutant genes and the expression of
PDL1 in different types of lung cancer. Methods This retrospective analysis was conducted …
PDL1 in different types of lung cancer. Methods This retrospective analysis was conducted …
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
L Zeng, L Song, L Liu, F Wu, Q Xu, H Yan, S Lin… - Med, 2024 - cell.com
Background BEBT-109 is an oral pan-mutant-selective inhibitor of epidermal growth factor
receptor (EGFR) that demonstrated promising antitumor potency in preclinical models …
receptor (EGFR) that demonstrated promising antitumor potency in preclinical models …
Organ‐restricted vascular delivery of nanoparticles for lung cancer therapy
DA Bölükbas, S Datz… - Advanced …, 2020 - Wiley Online Library
Nanoparticle‐based targeted drug delivery holds promise for treatment of cancers. However,
most approaches fail to be translated into clinical success due to ineffective tumor targeting …
most approaches fail to be translated into clinical success due to ineffective tumor targeting …
[HTML][HTML] lncRNA EPS15-AS1 affects the biological behavior of liver cancer stem cells by regulating EPS15 expression
G Liu, Y Lan, X Yin, T Wu - American Journal of Translational …, 2022 - ncbi.nlm.nih.gov
Objective: To investigate whether long non-coding RNA (lncRNA) EPS15-antisense RNA
(EPS15-AS1) affects the biological behavior of liver cancer stem cells (LCSCs) by targeting …
(EPS15-AS1) affects the biological behavior of liver cancer stem cells (LCSCs) by targeting …
Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa
Y Boustany, A Laraqui, H El Rhaffouli, T Bajjou… - 2022 - journals.sagepub.com
Objectives This study aims to analyze the prevalence and spectrum of epidermal growth
factor receptor (EGFR) mutations within the Middle East and North Africa region, compare …
factor receptor (EGFR) mutations within the Middle East and North Africa region, compare …
[HTML][HTML] WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations
Q Zheng, D Chen, X Wang, Y Yang… - Annals of …, 2022 - ncbi.nlm.nih.gov
Background To evaluate the safety and therapeutic efficacy of WX-0593, a newly developed
potent anaplastic lymphoma kinase (ALK) inhibitor, in combination with an epithelial growth …
potent anaplastic lymphoma kinase (ALK) inhibitor, in combination with an epithelial growth …
Bispecific antibodies: A novel approach for the treatment of solid tumors
Advancement in sequencing technologies allows for the identification of molecular pathways
involved in tumor progression and treatment resistance. Implementation of novel agents …
involved in tumor progression and treatment resistance. Implementation of novel agents …